Bioconjugated Calcium Phosphosilicate Nanoparticles for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer diagnosis and treatment modalities are inadequate, particularly for pancreatic and breast cancers, due to late diagnoses and the lack of effective systemic therapies, with existing nanotechnology limited in simultaneously seeking, treating, and imaging cancerous lesions effectively.
Innovation Solution
Development of bioconjugated calcium phosphosilicate nanoparticles (CPNPs) that can be systemically targeted to specific tissues by attaching molecular moieties recognizing cancerous cells, allowing for both imaging and therapeutic delivery, including the use of avidin-biotin coupling, maleimide covalent coupling, and Sulfo NHS coupling strategies to target transferrin, gastrin, and CD117 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If passive targeting via EPR effect is used, then nanoparticle accumulation in tumors is improved, but selective targeting of cancerous cells is insufficient leading to off-target toxicity
Solution Approach 1:
The patent introduces targeting moieties (antibodies, peptides, ligands) as intermediary molecules that mediate specific binding between nanoparticles and cancer cell surface markers. This intermediary layer enables selective recognition and binding to overexpressed receptors on cancerous cells while avoiding normal cells, thereby resolving the contradiction between tumor accumulation and off-target toxicity
Solution Approach 2:
The patent applies local quality by functionalizing only the surface of nanoparticles with specific targeting moieties, creating localized recognition sites that confer selective targeting capability. The core nanoparticle structure maintains general tumor accumulation properties while the surface functionalization provides specific cancer cell recognition, achieving both tumor accumulation and reduced off-target toxicity
2Reliability
If high doses of chemotherapeutic drugs are administered, then therapeutic benefit is improved, but systemic toxicity increases
Solution Approach 1:
The patent concentrates therapeutic drugs locally within the nanoparticle structure and delivers them specifically to cancer cells through active targeting. This localized drug delivery approach enables high drug concentrations at the tumor site (improving therapeutic benefit) while minimizing drug exposure to healthy tissues (reducing systemic toxicity)
Solution Approach 2:
The nanoparticle acts as an intermediary carrier that protects chemotherapeutic drugs from premature degradation and off-target interaction during circulation. The targeting moieties on the nanoparticle surface guide the drug-carrying nanoparticle specifically to cancer cells, enabling effective drug delivery at lower systemic doses and reducing systemic toxicity
3Adaptability or versatility
If multiple therapeutic and imaging agents are incorporated, then theranostic capability is improved, but nanoparticle complexity increases
Solution Approach 1:
The patent merges multiple functional components (therapeutic drugs, imaging agents, targeting moieties) into a single integrated nanoparticle platform. This consolidation enables simultaneous diagnostic imaging and therapeutic delivery (theranostics) while managing complexity through unified nanoparticle design rather than separate systems
Solution Approach 2:
The patent creates a universal nanoparticle platform with modular functional components that can be configured for different therapeutic and imaging applications. The core nanoparticle structure serves multiple functions (drug delivery, imaging, targeting) while allowing customization through interchangeable targeting moieties and payload combinations, achieving versatility without proportionally increasing complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bioconjugated CPNPs effectively target and image breast, pancreatic, and leukemic cancers, reducing off-target toxicity and improving therapeutic efficacy by concentrating therapeutic agents in target tissues while minimizing systemic concentrations, and demonstrate the ability to cross the blood-brain barrier.
Implementation Method 1
Initial in vivo imaging trials demonstrated that CPNPs, functionalized with polyethylene glycol (PEG) moieties, accumulated within solid tumors via an enhanced permeation retention (EPR) effect
Implementation Method 2
At pH 7.4, the CPNPs are sparingly soluble, but the CPNPs dissolve in the late stage endolysosomes at pH 4 to 5
Data Source
AI summary
Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.